101. Current management of NAFLD/NASH
- Author
-
Ana Carolina Cardoso, Claudio Figueiredo‐Mendes, Cristiane A. Villela‐Nogueira, and Luca Valenti
- Subjects
Metabolic Syndrome ,medicine.medical_specialty ,Hepatology ,business.industry ,Physical activity ,Disease ,medicine.disease ,Obesity ,Approved drug ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Current management ,Non-alcoholic Fatty Liver Disease ,030220 oncology & carcinogenesis ,Diabetes mellitus ,Medicine ,Humans ,030211 gastroenterology & hepatology ,Metabolic syndrome ,business ,Intensive care medicine ,Exercise ,Life Style - Abstract
NAFLD is the most common cause of liver disease worldwide, and its prevalence is significantly increasing. Studies have shown that it is associated with comorbidities such as diabetes, metabolic syndrome and obesity. Early diagnosis and management are highly important and could modify the prognosis of the disease. Evaluating the possibility of multiple aetiologies and recognizing the additional causes of liver disease should be a part of the patient's initial assessment. There are no approved drug treatments as yet, so the main management strategies should involve lifestyle changes such as physical activity and dietary re-education.
- Published
- 2021